I'll then provide a financial overview and comments with respect to our cash position, details on our investments in research and development activities, as well as updated financial guidance for 2012.
Robert will then conclude the call with additional comments regarding recent activities and expected next steps for our development stage programs as well as an update regarding projected company milestones for the remainder of 2012. We will then open the call for a brief question and answer session.
The following discussion including our responses to questions contain statements that constitute forward-looking statements for the purposes of the Safe Harbor provisions of the private securities litigation reform act of 1995. Including but not limited to statements relating to our financial guidance, to the initiation enrollment designed conduct and results of clinical trials, and to other research and development activities.
Our actual results might differ materially from those projected in these forward-looking statements. Additional information concerning factors that could cause our actual results to differ materially from those forward-looking statements is contained in our SEC filings including our most recent annual report on form 10-K, our quarterly reports on form 10-Q, and our current reports on form AK. Copies of these documents may be obtained from the SEC or by visiting the investor relations section of our website. These forward-looking statements speak only as of today. You should not rely on them as representing our views in the future. And we undertake no obligation to update these statements after this call.Now I'll turn the call over to Robert. Robert Blum
Thank you, Sharon. During the second quarter, we took important steps to insure that we continue to build on the progress reported in the first quarter. And remain focused to key value driving milestones. In recent months, we have received notifications of each of the United States adopted names or USA End Council and the World Health Organizations Consultation on International Non-Proprietary Names for pharmaceutical substances program that indicated the adoption of tirasemtiv as the generic name for CK-2017357. Going forward and on this call today, we will use the newly adopted generic name tirasemtiv when referring to the lead development compound in our skeletal muscle activator program directed to the potential treatment of Amyotrophic lateral sclerosis or ALS.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV